NEUROMAGEN PHARMA
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS. Neuromagen Pharma was founded in 2021 and was headquartered in Beer Sheva, Israel.
NEUROMAGEN PHARMA
Industry:
Biopharma Biotechnology Neuroscience
Founded:
2021-01-01
Address:
Be'er Sheva, HaDarom, Israel
Country:
Israel
Website Url:
http://www.neuromagen.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome Global Site Tag
Current Employees Featured
Founder
Official Site Inspections
http://www.neuromagen.com
- Host name: do13.imark.co.il
- IP address: 161.35.72.86
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Neuromagen Pharma"
Neuromagen Pharma Ltd.
Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules which activate Telomerase Reverse Transcriptase (TERT) โ an enzyme which โฆSee details»
Neuromagen Pharma - Crunchbase Company Profile & Funding
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS. Neuromagen Pharma was founded in 2021 and was headquartered in Beer Sheva, Israel.See details»
Neuromagen Pharma - VentureRadar
Website: https://www.neuromagen.com/ Develops innovative small molecules activating Telomerase Reverse Transcriptase, preventing cellular senescence and demonstrating โฆSee details»
Neuromagen Pharma - PitchBook
Developer of a novel drug designed for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis. The company's drug boosts the effectiveness of telomerase as a โฆSee details»
Neuromagen Pharma - Foreign Startup | Startup Nation Finder
Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT), an enzyme that plays a โฆSee details»
Neuromagen Pharma - LinkedIn
Neuromagen Pharma is an early-stage pharmaceutical company developing a new class of innovative small molecules which activate telomerase reverse transcriptase (TERT) โ an enzyme which plays a...See details»
Neuromagen Pharma - Products, Competitors, Financials, โฆ
Neuromagen Pharma is a pharmaceutical company focused on developing small molecule drugs for treating neurodegenerative diseases. Use the CB Insights Platform to explore Neuromagen โฆSee details»
Neuromagen Pharma - Tech Stack, Apps, Patents & Trademarks
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.See details»
Neuromagen Pharma - Crunchbase
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.See details»
Neuromagen Pharma - Drug pipelines, Patents, Clinical trials
Explore Neuromagen Pharma with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Endocrinology and Metabolic Disease, Immune System Diseases, Nervous โฆSee details»
Israeli drug that slowed Alzheimerโs, ALS in mice gets โฆ
Nov 2, 2021ย ยท They formed a company, Neuromagen Pharma, but did not have the funds to start the pre-clinical trials needed to prepare for human trials. Now, an Israeli funder has come up with the...See details»
Neuromagen Pharma Announces the Approval of a NIS 1.8M โฆ
Mar 21, 2022ย ยท Neuromagen is developing a family of patent protected small molecule activators of telomerase reverse transcriptase โ a key aging related enzyme which is associated with โฆSee details»
Neuromagen Pharma - Contacts, Employees, Board Members
Neuromagen Pharma has 1 current employee profile, CEO & Co-Founder Gil Ben Menachem. Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.See details»
Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation โฆ
May 5, 2022ย ยท Neuromagen Pharma Ltd. is an early-stage pharmaceutical company developing a new class of innovative small molecules which activate telomerase reverse transcriptase โฆSee details»
Potential ALS drug gets boost toward preclinical trials
Nov 3, 2021ย ยท A new class of small molecules for treating amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigโs Disease, and other neurodegenerative diseases, is being developed at โฆSee details»
AGS-534 - Drug Targets, Indications, Patents - Synapse
AGS-534: a Telomerase activators Drug, Initially developed by Ben-Gurion University of the Negev, Now, its global highest R&D status is Preclinical, Mechanism: Telomerase โฆSee details»
Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation โฆ
05 May 2022 โ Congratulations to Neuromagen Pharma Ltd. on their recent Orphan Drug Designation for AGS-499, its lead drug candidate. AGS-499 has shown significant โฆSee details»
Gil Ben Menachem - CEO & Co-Founder @ Neuromagen Pharma
Gil Ben Menachem is the Co-Founder and CEO of Neuromagen Pharma. He previously worked at Kitov Pharma as a Vice President Of Business Development. Gil Ben Menachem attended the โฆSee details»
Neuromagen Receives FDA Orphan Drug to Slow Progression of ALS
May 9, 2022ย ยท Israeli Neuromagen Pharma Ltd., a developer of drugs to treat degenerative and senescence-associated diseases, has received FDA Orphan Drug Designation for its lead โฆSee details»